United States. Securities and Exchange Commission
Vertex Pharmaceuticals Inc., a leading developer of innovative medicines for the treatment of serious diseases, recently filed a Form 4 document with the U.S. Securities and Exchange Commission (SEC). The filing, which was received on February 27, 2015, provides detailed information about the company's equity securities and
United States. Securities and Exchange Commission
Xoma Corp., a pharmaceutical preparations company based in California, has filed a SEC Form 4 filing with the U.S. Securities and Exchange Commission (SEC). The filing, which was posted on March 2, 2015, contains information on the company's ownership and transactions involving its equity securities. The SEC
Scientists
Researchers from Tianjin Medical University conducted a study to investigate the potential feasibility of tumor-targeted drug delivery using folic acid and TAT peptide-conjugated polymeric liposomes. The study aimed to evaluate the in vitro and in vivo antitumor activity of paclitaxel-loaded, folic-acid-targeted and TAT-peptide-conjugated polymeric liposomes (FA-TATp-PLs) in KB and A549
Scientists
Researchers at Iwate University have discovered that nitric oxide (NO) plays a crucial role in anoikis, a process of programmed cell death, in human gastric carcinoma cells infected with Mycoplasma hyorhinis. The study found that NO production, activated by iNOS mRNA synthesis, triggers anoikis through the attenuation of E-cadherin and
Pharmaceutical industry
According to a study from Basingstoke, the United Kingdom, schizophrenia patients have a potential increased risk of metabolic dysregulation during antipsychotic treatments. The study compared changes in prolactin and metabolic variables (glucose, lipids, and weight) in patients treated with olanzapine or quetiapine. The researchers found that patients treated with olanzapine
Pharmaceutical industry
Cephalon, Inc. (NASDAQ:CEPH) has partnered with the American Chronic Pain Association (ACPA) and the American Pharmacists Association (APhA) to expand its When Good Medicines Become Bad Drugs(SM) program. The program aims to educate patients, caregivers, and the public about the abuse of prescription medications, which affects approximately six
Drugs
Scientists at Kanazawa University's Cancer Research Institute have discovered a novel mechanism of resistance to irreversible epidermal growth factor receptor (EGFR) inhibitors in lung cancer patients. The study, published in Clinical Cancer Research, found that hepatocyte growth factor (HGF) reduces susceptibility to the irreversible EGFR tyrosine kinase inhibitor
Drugs
Recent research published in the British Journal of Pharmacology reveals that checkpoint kinase 2 (CHK2) modulates the response of colorectal cancer cells to oxaliplatin treatment. The study, led by I.M. Pires and colleagues from the University of Manchester, investigated the role of CHK2 in oxaliplatin-induced toxicity in colorectal cancer
Drugs
SGX523, a novel ATP-competitive kinase inhibitor, has been shown to exhibit exquisite selectivity for the MET receptor tyrosine kinase, making it a promising tool for cancer research. Researchers report that SGX523 potently inhibits MET with an IC50 of 4 nmol/L, demonstrating 1,000-fold selectivity versus other protein kinases tested
Drugs
In a remarkable case, a patient with advanced renal cell carcinoma (RCC) achieved complete remission after undergoing adoptive immunotherapy using activated autologous gammadelta T-cells. The 2-year remission milestone, with no additional treatment required, is a significant breakthrough in cancer gene therapy. Researchers at Tokyo Women's Medical University, led
Drugs
In a landmark study published in Biochimica Et Biophysica Acta, researchers from Harvard University and Dana-Farber Cancer Institute have shed light on the structural and mechanistic underpinnings of EGFR mutations in non-small cell lung cancer. The study explores the exquisite sensitivity of a subset of lung cancer mutants to gefitinib
Drugs
Research published in the Oncology Reports journal has found that resveratrol, a compound found in red wine and several other plant-based foods, can induce apoptosis in multidrug-resistant human lung cancer cells. The study, conducted by W. Zhao and colleagues from the Chinese PLA General Hospital, Department of Respiratory Medicine, involved
